MCID: ACT135
MIFTS: 53

Acute Graft Versus Host Disease malady

Categories: Rare diseases, Blood diseases

Aliases & Classifications for Acute Graft Versus Host Disease

Aliases & Descriptions for Acute Graft Versus Host Disease:

Name: Acute Graft Versus Host Disease 50 56
Acute Graft-Versus-Host Disease 52
Acute Gvh Disease 69
Acute Gvhd 50

Classifications:

Orphanet: 56  
Rare immunological diseases


External Ids:

Orphanet 56 ORPHA99920
ICD10 via Orphanet 34 T86.0

Summaries for Acute Graft Versus Host Disease

MalaCards based summary : Acute Graft Versus Host Disease, also known as acute graft-versus-host disease, is related to hepatitis and clostridium difficile colitis. An important gene associated with Acute Graft Versus Host Disease is TNF (Tumor Necrosis Factor), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Cyclosporine and Tacrolimus have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and bone marrow, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and cellular

Related Diseases for Acute Graft Versus Host Disease

Diseases in the Acute Graft Versus Host Disease family:

Chronic Graft Versus Host Disease

Diseases related to Acute Graft Versus Host Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 246)
id Related Disease Score Top Affiliating Genes
1 hepatitis 30.0 IFNG IL10 IL2 TNF
2 clostridium difficile colitis 29.7 IFNG IL2 IL4 TNF
3 hematopoietic stem cell transplantation 10.7
4 leukemia 10.4
5 pyridoxal 5'-phosphate-dependent epilepsy 10.3 IL10 TNF
6 steatitis 10.3 IL2 TNF
7 myoglobinuria recurrent 10.3 IFNG IL4
8 stocco dos santos syndrome 10.3 IFNG TNF
9 paralytic poliomyelitis 10.3 IFNG IL2
10 caplan's syndrome 10.3 IFNG IL2
11 sarcoma 10.2 IL2 IL4
12 vulvar vestibulitis syndrome 10.2 IL2 IL4
13 multiple vertebral anomalies unusual facies 10.2 IL10 TNF
14 ceroid lipofuscinosis, neuronal, 3 10.2 IL10 IL4
15 chronic thromboembolic pulmonary hypertension 10.2 IFNG IL10 IL2
16 tau syndrome 10.2 IL18 TNF
17 senile reticular retinal degeneration 10.2 IFNG IL10 TNF
18 conduct disorder 10.2 IFNG IL10 TNF
19 pancreatic signet ring cell adenocarcinoma 10.2 IFNG IL10 TNF
20 oropharynx cancer 10.2 IFNG IL10 IL2
21 pulpitis 10.2 IFNG IL10 TNF
22 ciliary discoordination, due to random ciliary orientation 10.2 IFNG IL10 IL2RA
23 hereditary alpha tryptasemia syndrome 10.2 IFNG IL10 TNF
24 rickettsialpox 10.2 IFNG IL10 TNF
25 diabetic angiopathy 10.2 IL10 IL4
26 plummer's disease 10.2 IFNG IL10 TNF
27 endotheliitis 10.2
28 hemangioma of intra-abdominal structure 10.2 FASLG IFNG
29 disease of mental health 10.2 IFNG IL10 TNF
30 follicular adenoma 10.2 IFNG IL10 TNF
31 tungiasis 10.2 IFNG IL10 IL4
32 centronuclear myopathy 5 10.2 IFNG IL10 IL4
33 tubular renal disease-cardiomyopathy syndrome 10.2 IL10 IL4 TNF
34 depressed scar 10.2 IFNG IL10 TNF
35 strawberry gallbladder 10.2 IFNG IL2 TNF
36 lagophthalmos 10.2 IL10 IL4 TNF
37 distal trisomy 14q 10.2 IFNG TNF
38 conidiobolomycosis 10.2 IL10 IL4 TNF
39 classic type lipoma 10.2 IFNG IL10 TNF
40 multiple epiphyseal dysplasia due to collagen 9 anomaly 10.2 IFNG IL2 IL4
41 vestibule of mouth cancer 10.2 IL10 IL4 TNF
42 t-cell prolymphocytic leukemia 10.2 IL2RA TNF
43 loiasis 10.2 IFNG IL10 IL4
44 congenital hypothyroidism 10.2 IL10 IL4 TNF
45 fungal gastritis 10.2 IFNG IL10 TNF
46 proximal symphalangism 10.2 IFNG IL10 IL4
47 lung combined large cell neuroendocrine carcinoma 10.2 IL10 IL2 IL4
48 urethral intrinsic sphincter deficiency 10.2 IFNG IL4 TNF
49 sclerosing adenosis of breast 10.2 IFNG IL10 TNF
50 hypotrichosis 4 10.2 IFNG IL4 TNF

Graphical network of the top 20 diseases related to Acute Graft Versus Host Disease:



Diseases related to Acute Graft Versus Host Disease

Symptoms & Phenotypes for Acute Graft Versus Host Disease

GenomeRNAi Phenotypes related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.78 NOD2 TNF GZMB IL10 IL18 IL2
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.78 TNF GZMB IL10 IL18 IL2 IL2RA

MGI Mouse Phenotypes related to Acute Graft Versus Host Disease:

44 (show all 14)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.24 TNF TNFRSF4 FASLG IFNG IL10 IL18
2 digestive/alimentary MP:0005381 10.22 FASLG IFNG IL10 IL18 IL2 IL2RA
3 hematopoietic system MP:0005397 10.22 IL10 IL18 IL2 IL2RA IL4 MYH9
4 homeostasis/metabolism MP:0005376 10.2 MYH9 NOD2 TNF TNFRSF4 FASLG IFNG
5 growth/size/body region MP:0005378 10.19 TNF TNFRSF4 IFNG IL10 IL18 IL2
6 immune system MP:0005387 10.17 FASLG IFNG IL10 IL18 IL2 IL2RA
7 mortality/aging MP:0010768 10.06 FASLG IFNG IL10 IL18 IL2 IL2RA
8 endocrine/exocrine gland MP:0005379 10.05 FASLG IFNG IL10 IL2 IL2RA IL4
9 integument MP:0010771 9.95 FASLG IFNG IL10 IL18 IL4 TNF
10 liver/biliary system MP:0005370 9.91 FASLG IFNG IL10 IL2 IL4 TNF
11 neoplasm MP:0002006 9.65 FASLG IFNG IL10 IL2 TNF
12 no phenotypic analysis MP:0003012 9.63 IFNG IL10 IL2 IL4 MYH9 TNF
13 respiratory system MP:0005388 9.56 FASLG IFNG IL10 IL2 IL2RA IL4
14 vision/eye MP:0005391 9.28 TNF FASLG IFNG IL10 IL18 IL2

Drugs & Therapeutics for Acute Graft Versus Host Disease

Drugs for Acute Graft Versus Host Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 386)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
2
Tacrolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 104987-11-3 445643 439492
3
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147-94-4 6253
4
Methotrexate Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 1959-05-2, 59-05-2 126941
5
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
6
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 24280-93-1 446541
7
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 128794-94-5 5281078
8
Ganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2 82410-32-0 3454
9
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 21679-14-1, 75607-67-9 30751
10
Vidarabine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 24356-66-9 32326 21704
11
Busulfan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 55-98-1 2478
12
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 22916-47-8 4189
13
Basiliximab Approved, Investigational Phase 4,Phase 3,Phase 2 152923-56-3, 179045-86-4
14
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
15
Foscarnet Approved Phase 4,Phase 2 63585-09-1, 4428-95-9 3415
16
Thiotepa Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 52-24-4 5453
17
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
18
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353
19
Infliximab Approved Phase 4,Phase 2,Phase 1 170277-31-3
20
Daclizumab Approved, Investigational Phase 4,Phase 3,Phase 2 152923-56-3
21
Menthol Approved Phase 4,Phase 2,Phase 1 2216-51-5 16666
22
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
23
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
24
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
25
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 58-05-9 54575, 6560146 143
26
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 59-30-3 6037
27
Phosphonoacetic Acid Experimental Phase 4,Phase 2 4408-78-0 546
28 Alkylating Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
29 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
30 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Folic Acid Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
32 Ganciclovir triphosphate Phase 4,Phase 3,Phase 2
33 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
35 Dermatologic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
36 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
37
Treosulfan Phase 4,Phase 3,Phase 2 299-75-2 9296
38 Hormones Phase 4,Phase 3,Phase 2,Phase 1
39 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
40 Vitamin B Complex Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
41 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Immunoglobulins Phase 4,Phase 2,Phase 3,Phase 1
43 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
44 Antibodies, Monoclonal Phase 4,Phase 2,Phase 3,Phase 1
45 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
46 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
47 Antifungal Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
48 Antilymphocyte Serum Phase 4,Phase 3,Phase 2,Phase 1
49 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Anti-Retroviral Agents Phase 4,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 996)
id Name Status NCT ID Phase
1 Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD Completed NCT00574470 Phase 4
2 Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule/Injection) and Methotrexate (MTX) Combination Therapy for Prevention of Graft Versus Host Disease (GVHD) in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation Fro Completed NCT02660684 Phase 4
3 Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCT Completed NCT01232504 Phase 4
4 A Study Comparing the Withdrawal of Steroids or Tacrolimus in Kidney Transplant Recipients Completed NCT00195429 Phase 4
5 Study Comparing Cyclosporine Dose Reduction vs. Cyclosporine Elimination in Kidney Transplant Recipients Taking Sirolimus Completed NCT00195468 Phase 4
6 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4
7 Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major Recruiting NCT02342145 Phase 4
8 Efficacy and Safety Study of ATG for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT Recruiting NCT02677181 Phase 4
9 Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT Recruiting NCT02634294 Phase 4
10 Post-transplantation Cyclophosphamide for Haploidentical Transplant From Maternal or Collateral Donors Recruiting NCT02412423 Phase 4
11 Anti-thymocyte Globulins for Graft-versus-host Disease Prophylaxis Recruiting NCT01856803 Phase 4
12 Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections Recruiting NCT02805946 Phase 4
13 Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients Recruiting NCT03150134 Phase 4
14 CMV-CTL for the Treatment of CMV Infection After HSCT Recruiting NCT03004261 Phase 4
15 ALL SCTped FORUM - Pharmacogenomic Study (add-on Study) Recruiting NCT02670564 Phase 4
16 Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major Recruiting NCT03171831 Phase 4
17 Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation Not yet recruiting NCT02784561 Phase 4
18 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT Not yet recruiting NCT03176849 Phase 4
19 Extracorporeal Photopheresis for Acute Graft Versus Host Disease Unknown status NCT00179855 Phase 2, Phase 3
20 MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis Unknown status NCT02270307 Phase 2, Phase 3
21 Randomized Study of ATG for Graft Versus Host Disease (GVHD) Prevention in Paediatric Patients Given an Unrelated Donor Stem Cell Transplantation Unknown status NCT00934557 Phase 3
22 Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation Unknown status NCT00207792 Phase 3
23 Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia Unknown status NCT01423747 Phase 3
24 ALL-SCT BFM International- HSCT in Children and Adolescents With ALL Unknown status NCT01423500 Phase 3
25 Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation Unknown status NCT01217723 Phase 3
26 Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis Unknown status NCT01238328 Phase 2, Phase 3
27 Hematopoietic Stem Cell Transplantation for Malignant Infantile Osteopetrosis Unknown status NCT01087398 Phase 2, Phase 3
28 Unrelated Double Umbilical Cord Blood Units Transplantation Unknown status NCT01015742 Phase 2, Phase 3
29 Randomised Prospective Comparison of the NMA Allograft and the Traditional Allograft in Acute Myeloid Leukaemia Unknown status NCT00224614 Phase 3
30 The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease Completed NCT00726375 Phase 3
31 Study Comparing ABX-CBL (Monoclonal Antibody) Versus Atgam in Patients With Steroid Resistant Acute Graft Versus Host Disease Completed NCT00035880 Phase 2, Phase 3
32 Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease Completed NCT00929695 Phase 3
33 Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease Completed NCT00366145 Phase 3
34 Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host Disease Completed NCT00053976 Phase 3
35 Efficacy and Safety of Prochymal™ Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute GVHD Completed NCT00562497 Phase 3
36 Acute Graft-Versus-Host Disease (aGvHD) Prophylaxis With ATG-Fresenius in Matched Unrelated Donor-Stem Cell Transplantation (MUD-SCT) Completed NCT00655343 Phase 3
37 Acute Graft-versus-Host Disease Treatment (BMT CTN 0802) Completed NCT01002742 Phase 3
38 Tacrolimus/Methotrexate Versus Cyclosporine/Methotrexate for Prophylaxis of Graft Versus Host Disease Completed NCT01788501 Phase 2, Phase 3
39 Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00152139 Phase 3
40 Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation Completed NCT00002456 Phase 3
41 Thymoglobuline in Non-myeloablative Allogeneic Stem-cell Transplantation Completed NCT00130754 Phase 3
42 Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) Completed NCT00406393 Phase 3
43 Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia Completed NCT00678275 Phase 3
44 Budesonide for Prevention of Acute Gastrointestinal GVHD Following Allogenic Stem Cell Transplantation Completed NCT00180089 Phase 3
45 Randomized Trial Comparing Sirolimus and Tacrolimus Versus Cyclosporine and Methotrexate as Graft-versus-host Disease (GVHD) Prophylaxis After Allogeneic Stem Cell Transplantation Completed NCT00993343 Phase 3
46 Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation Completed NCT00004255 Phase 2, Phase 3
47 Peripheral Blood (PB) Versus Bone Marrow (BM) in Allogeneic Stem Cell Transplantation Completed NCT01020175 Phase 3
48 Stem Cell Transplant for Inborn Errors of Metabolism Completed NCT00176904 Phase 2, Phase 3
49 Nonmyeloablative Stem Cell Transplant in Elderly Completed NCT00382759 Phase 2, Phase 3
50 C-Reactive Protein as a Predictor of Stem Cell Transplant Complications Completed NCT00179868 Phase 2, Phase 3

Search NIH Clinical Center for Acute Graft Versus Host Disease

Genetic Tests for Acute Graft Versus Host Disease

Anatomical Context for Acute Graft Versus Host Disease

MalaCards organs/tissues related to Acute Graft Versus Host Disease:

39
T Cells, Bone, Bone Marrow, Liver, Skin, Endothelial, Myeloid

Publications for Acute Graft Versus Host Disease

Articles related to Acute Graft Versus Host Disease:

(show top 50) (show all 710)
id Title Authors Year
1
The Combination of Cyclosporine and Mycophenolate Mofetil is Less Effective than Cyclosporine and Methotrexate in the Prevention of Acute Graft-versus Host Disease after Stem-cell Transplantation from Unrelated Donors. ( 28052467 )
2017
2
Mycophenolate mofetil is effective only for involved skin in the treatment for steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. ( 27766393 )
2017
3
Cutaneous acute graft-versus-host disease with isomorphic disposition over striae distensae in a 12-year-old girl. ( 27805255 )
2017
4
Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFA. ( 28088653 )
2017
5
The role of danger signals and ectonucleotidases in acute graft-versus-host disease. ( 26902992 )
2016
6
Fecal microbiota transplantation for patients with steroid-resistant/dependent acute graft-versus-host disease of the gut. ( 27461930 )
2016
7
Treatment of acute graft-versus-host disease. ( 27795528 )
2016
8
Circulating miRNA panel for prediction of acute graft-versus-host disease inA lymphoma patients undergoing matched unrelated hematopoietic stem cellA transplantation. ( 27013207 )
2016
9
The Role of Purine Metabolites as DAMPs in Acute Graft-versus-Host Disease. ( 27818661 )
2016
10
Pretransplant I^2-Microglobulin Is Associated with the Risk of Acute Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplant. ( 27044906 )
2016
11
Post-Transplantation Natural Killer Cell Count: A Predictor of Acute Graft-Versus-Host Disease and Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation. ( 27375156 )
2016
12
GRIM19 ameliorates acute graft-versus-host disease (GVHD) by modulating Th17 and Treg cell balance through down-regulation of STAT3 and NF-AT activation. ( 27391226 )
2016
13
Extracellular vesicles released from human umbilical cord-derived mesenchymal stromal cells prevent life-threatening acute graft-versus-host disease in a mouse model of allogeneic hematopoietic stem cell transplantation. ( 27649744 )
2016
14
Organsiderosis and hemophagocytosis during acute graft-versus-host disease. ( 27198715 )
2016
15
A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus-Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses. ( 27498124 )
2016
16
IL-22 promoted CD3+ T cell infiltration by IL-22R induced STAT3 phosphorylation in murine acute graft versus host disease target organs after allogeneic bone marrow transplantation. ( 27551984 )
2016
17
The Potential of Mesenchymal Stromal Cells as Treatment for Severe Steroid-Refractory Acute Graft-Versus-Host Disease: A Critical Review of the Literature. ( 26714122 )
2016
18
Extracoporeal photopheresis treatment of acute graft-versus-host disease following allogeneic haematopoietic stem cell transplantation. ( 27408705 )
2016
19
Controlled, Randomized, Open-Label Trial of Risk-Stratified Corticosteroid Prevention of Acute Graft-Versus-Host Disease After Haploidentical Transplantation. ( 27091717 )
2016
20
Donor Killer Immunoglobulin-Like Receptor Haplotype B/X Induces Severe Acute Graft-Versus-Host Disease in the Presence of HLA Mismatch in T-Cell Replete Hematopoietic Cell Transplantation. ( 28042021 )
2016
21
Donor-Derived Regulatory T Cells Attenuate the Severity of Acute Graft-Versus-Host Disease after Cord Blood Transplantation. ( 27356468 )
2016
22
Unique patterns of CD8+ T-cell-mediated organ damage in the Act-mOVA/OT-I model of acute graft-versus-host disease. ( 27137185 )
2016
23
Successful salvage treatment of acute graft-versus-host disease after liver transplantation by withdrawal of immunosuppression: a case report. ( 26925149 )
2016
24
Correlation of Tc17 cells at early stages after allogeneic hematopoietic stem cell transplantation with acute graft-versus-host disease. ( 27846420 )
2016
25
A Prospective Study of Alemtuzumab as a Second Line Agent for Steroid Refractory Acute Graft Versus Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplant. ( 27664325 )
2016
26
Recipient and donor JAK2 46/1 haplotypes are associated with acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. ( 27389386 )
2016
27
Vascular Alterations in a Murine Model of Acute Graft-Versus-Host Disease Are Associated With Decreased Serum Levels of Adiponectin and an Increased Activity and Vascular Expression of Indoleamine 2,3-Dioxygenase. ( 27931514 )
2016
28
Late acute graft versus host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors. ( 27625357 )
2016
29
Conjunctival Acute Graft-versus-Host Disease in Adult Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Cohort Study. ( 27902756 )
2016
30
Evaluation of interleukin 12 and CD56+ lymphocyte cells in pediatric hematopoietic stem cell transplantation for early diagnosis of acute graft versus host disease. ( 27751764 )
2016
31
Late-onset acute graft-versus-host disease mimicking hand, foot, and mouth disease. ( 27990387 )
2016
32
High-risk HLA alleles for severe acute graft-versus-host disease and mortality in unrelated donor bone marrow transplantation. ( 26768690 )
2016
33
miR-146a and miR-155 Expression Levels in Acute Graft-Versus-Host Disease Incidence. ( 27014257 )
2016
34
High expression of heme oxygenase-1 in target organs may attenuate acute graft-versus-host disease through regulation of immune balance of TH17/Treg. ( 27168057 )
2016
35
Effect of Everolimus (RAD001) on Acute Graft-Versus-Host Disease in Mice. ( 27379528 )
2016
36
Donor Cell Composition and Reactivity Predict Risk of Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. ( 27965986 )
2016
37
T-bet Promotes Acute Graft-versus-Host Disease by Regulating Recipient Hematopoietic Cells in Mice. ( 26903480 )
2016
38
Recombinant IL-7/HGFI^ hybrid cytokine separates acute graft-versus-host-disease from graft-versus-tumour activity by altering donor T cell trafficking. ( 27447780 )
2016
39
Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease. ( 27595281 )
2016
40
Pathogenesis of acute graft-versus-host disease: from intestinal microbiota alterations to donor T cell activation. ( 27619472 )
2016
41
Endothelial microparticles carrying hedgehog-interacting protein induce continuous endothelial damage in the pathogenesis of acute graft-versus-host disease. ( 27009877 )
2016
42
Vascular alterations in a murine model of acute graft-versus-host disease are associated with decreased serum levels of adiponectin and an increased activity and vascular expression of indoleamine 2,3-dioxygenase. ( 27196361 )
2016
43
A mathematical model provides new insights into solid organ transplant-associated acute graft-versus-host disease. ( 27465565 )
2016
44
Mesenchymal stem cells provide prophylaxis against acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: A meta-analysis of animal models. ( 27528221 )
2016
45
The pretransplant systemic metabolic profile reflects a risk of acute graft versus host disease after allogeneic stem cell transplantation. ( 27829829 )
2016
46
miR-153-3p, a new bio-target, is involved in the pathogenesis of acute graft-versus-host disease via inhibition of indoleamine- 2,3-dioxygenase. ( 27340781 )
2016
47
Association of Cumulative Steroid Dose with Risk of Infection after Treatment for Severe Acute Graft-versus-Host Disease. ( 26968790 )
2016
48
Peritransplant Serum Albumin Decline Predicts Subsequent Severe Acute Graft-versus-Host Disease after Mucotoxic Myeloablative Conditioning. ( 26988741 )
2016
49
Treatment of acute graft versus host disease with mesancyhmal stem cells: Questions and answers. ( 26969103 )
2016
50
Effect of major histocompatibility complex haplotype matching by C4 and MICA genotyping on acute graft versus host disease in unrelated hematopoietic stem cell transplantation. ( 26602146 )
2016

Variations for Acute Graft Versus Host Disease

Expression for Acute Graft Versus Host Disease

Search GEO for disease gene expression data for Acute Graft Versus Host Disease.

Pathways for Acute Graft Versus Host Disease

Pathways related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 62)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.99 FASLG IFNG IL10 IL18 IL2 IL2RA
2
Show member pathways
13.81 FASLG IL10 IL18 IL2 IL2RA IL4
3
Show member pathways
13.65 FASLG IFNG IL10 IL18 IL2 IL2RA
4
Show member pathways
13.49 IFNG IL10 IL18 IL2 IL2RA IL4
5
Show member pathways
13.42 FASLG IL10 IL18 IL2 IL2RA IL4
6
Show member pathways
13.33 FASLG IFNG IL10 IL18 IL2 IL2RA
7
Show member pathways
13.3 FASLG IL10 IL18 IL2 IL2RA IL4
8
Show member pathways
12.88 FASLG IFNG IL10 IL2 TNF
9
Show member pathways
12.88 FASLG GZMB IFNG IL10 IL2 IL2RA
10
Show member pathways
12.83 FASLG IFNG IL18 IL2 IL2RA IL4
11
Show member pathways
12.68 IFNG IL10 IL18 IL2 IL2RA IL4
12
Show member pathways
12.61 IFNG IL10 IL18 IL2 TNF
13
Show member pathways
12.58 FASLG GZMB IFNG IL2 IL4 TNF
14
Show member pathways
12.57 IFNG IL10 IL18 IL2 IL2RA IL4
15 12.56 FASLG IL2 IL2RA IL4
16
Show member pathways
12.49 IFNG IL10 IL2 IL4 TNF
17 12.41 FASLG GZMB IFNG IL10 IL2 IL2RA
18
Show member pathways
12.33 IFNG IL2 IL4 TNF
19 12.3 IFNG IL10 IL18 NOD2 TNF
20
Show member pathways
12.28 IFNG IL10 IL2 IL2RA IL4
21
Show member pathways
12.27 IFNG IL10 IL4 TNF
22
Show member pathways
12.23 IFNG IL10 IL18 IL2 IL4 TNF
23
Show member pathways
12.2 FASLG IFNG IL4 TNF
24 12.08 FASLG IL10 IL18 IL4 TNF
25 12.06 IFNG IL2 IL4 TNF
26 12.06 IFNG IL10 IL2 IL2RA IL4 TNF
27
Show member pathways
12.03 IFNG IL2 IL2RA
28
Show member pathways
12.03 IFNG IL10 IL18 IL2 TNF
29
Show member pathways
11.92 FASLG GZMB IFNG IL18 IL2 IL2RA
30
Show member pathways
11.91 GZMB IFNG IL4
31 11.88 IL2RA IL4 TNF
32 11.88 IFNG IL10 TNF
33 11.85 IFNG IL18 TNF
34 11.85 IFNG IL10 IL2 TNF
35 11.82 IFNG IL18 MYH9
36
Show member pathways
11.82 FASLG TNF TNFRSF4
37 11.8 IFNG IL2 IL4
38 11.8 IL10 IL2RA IL4 TNF TNFRSF4
39
Show member pathways
11.79 FASLG IL2 IL2RA IL4
40 11.79 IFNG IL10 IL2 IL2RA
41
Show member pathways
11.76 FASLG IFNG IL2 IL2RA IL4 TNF
42
Show member pathways
11.68 IFNG IL2 TNF
43 11.65 FASLG IFNG IL2 TNF
44 11.63 IL10 IL18 IL4 TNF
45 11.62 IFNG IL10 IL18 TNF
46 11.55 IFNG IL2 TNF
47 11.55 IFNG IL18 TNF
48 11.52 FASLG IFNG TNF
49 11.52 IFNG IL10 IL2 IL2RA IL4 TNFRSF4
50
Show member pathways
11.49 FASLG GZMB IFNG IL2 IL2RA TNF

GO Terms for Acute Graft Versus Host Disease

Cellular components related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 FASLG IFNG IL10 IL18 IL2 IL4
2 cell surface GO:0009986 9.55 FASLG IL2RA NOD2 TNF TNFRSF4
3 extracellular space GO:0005615 9.5 FASLG IFNG IL10 IL18 IL2 IL4
4 external side of plasma membrane GO:0009897 9.02 FASLG IFNG IL2RA IL4 TNF

Biological processes related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
id Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.98 FASLG IL10 IL18 IL2
2 MAPK cascade GO:0000165 9.97 IL18 IL2 IL2RA TNF
3 inflammatory response GO:0006954 9.95 IL10 IL18 IL2RA TNF TNFRSF4
4 defense response to bacterium GO:0042742 9.94 IFNG IL10 NOD2 TNF
5 tumor necrosis factor-mediated signaling pathway GO:0033209 9.87 FASLG TNF TNFRSF4
6 cellular response to lipopolysaccharide GO:0071222 9.87 IFNG IL10 TNF
7 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.86 IL10 IL4 TNF
8 positive regulation of protein phosphorylation GO:0001934 9.86 IFNG IL2 IL4 TNF
9 negative regulation of inflammatory response GO:0050728 9.85 IL10 IL2 IL2RA
10 cellular response to organic cyclic compound GO:0071407 9.84 IL18 NOD2 TNF
11 apoptotic signaling pathway GO:0097190 9.83 FASLG TNF TNFRSF4
12 positive regulation of interferon-gamma production GO:0032729 9.79 IL18 IL2 TNF
13 extrinsic apoptotic signaling pathway GO:0097191 9.78 FASLG IFNG TNF
14 positive regulation of B cell proliferation GO:0030890 9.74 IL2 IL4 TNFRSF4
15 positive regulation of T cell proliferation GO:0042102 9.73 IFNG IL2 IL2RA IL4
16 positive regulation of protein complex assembly GO:0031334 9.72 IFNG TNF
17 positive regulation of interleukin-1 beta secretion GO:0050718 9.72 IFNG NOD2
18 positive regulation of interleukin-10 production GO:0032733 9.71 IL4 NOD2
19 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.71 NOD2 TNF
20 natural killer cell activation GO:0030101 9.71 IL18 IL2
21 positive regulation of NF-kappaB import into nucleus GO:0042346 9.71 IL18 TNF
22 negative regulation of myoblast differentiation GO:0045662 9.71 IL18 TNF
23 positive regulation of osteoclast differentiation GO:0045672 9.7 IFNG TNF
24 positive regulation of tyrosine phosphorylation of Stat5 protein GO:0042523 9.7 IL2 IL4
25 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.7 IL10 TNF
26 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.69 IFNG TNF
27 negative regulation of nitric oxide biosynthetic process GO:0045019 9.69 IL10 IL4
28 defense response to protozoan GO:0042832 9.69 IFNG IL10 IL4
29 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.68 IL10 TNF
30 positive regulation of immunoglobulin secretion GO:0051024 9.68 IL2 TNFRSF4
31 endothelial cell apoptotic process GO:0072577 9.67 IL10 TNF
32 positive regulation of T cell differentiation GO:0045582 9.67 IL2 IL2RA IL4
33 necroptotic signaling pathway GO:0097527 9.65 FASLG TNF
34 negative regulation of cytokine secretion involved in immune response GO:0002740 9.65 IL10 TNF
35 negative regulation of lymphocyte proliferation GO:0050672 9.65 IL2 IL2RA
36 negative regulation of growth of symbiont in host GO:0044130 9.65 IFNG IL10 TNF
37 positive regulation of tissue remodeling GO:0034105 9.64 IL18 IL2
38 regulation of isotype switching GO:0045191 9.63 IL10 IL4
39 positive regulation of interleukin-17 production GO:0032740 9.63 IL18 IL2 NOD2
40 negative regulation of T-helper 17 cell differentiation GO:2000320 9.62 IL2 IL4
41 positive regulation of mononuclear cell migration GO:0071677 9.62 IL4 TNF
42 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.62 IFNG IL18 IL2 IL4
43 receptor biosynthetic process GO:0032800 9.6 IL10 TNF
44 regulation of T cell homeostatic proliferation GO:0046013 9.59 IL2 IL2RA
45 inflammatory cell apoptotic process GO:0006925 9.58 FASLG IFNG
46 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.58 IFNG TNF
47 positive regulation of chemokine biosynthetic process GO:0045080 9.58 IFNG IL4 TNF
48 positive regulation of vitamin D biosynthetic process GO:0060557 9.54 IFNG TNF
49 positive regulation of isotype switching to IgG isotypes GO:0048304 9.54 IFNG IL2 IL4
50 positive regulation of MHC class II biosynthetic process GO:0045348 9.43 IFNG IL10 IL4

Molecular functions related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.17 FASLG IFNG IL10 IL18 IL2 IL4
2 growth factor activity GO:0008083 9.13 IL10 IL2 IL4

Sources for Acute Graft Versus Host Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....